ArticlemedRxiv : the preprint server for health sciences2026
An intraoperative methylene blue test can guide patient selection for totally tubeless PCNL.
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Introduction and Objective: Totally tubeless percutaneous nephrolithotomy (PCNL) has been demonstrated to be feasible and safe, particularly for mini-PCNL. Having an objective test to guide patient selection could improve confidence in this practice and facilitate broader adoption. The purpose of this study was to evaluate the utility of an intraoperative methylene blue test to determine candidacy for totally tubeless PCNL. Methods: Adult patients undergoing PCNL at four institutions were included in this study. Patients with prior reconstructive surgery, chronic pain, or requiring ureteral dilation were excluded. After stone clearance, 10 mL methylene blue (MB) dye was injected into the percutaneous access tract. A positive test ("pass") was defined as visualization of blue dye in the bladder catheter within two minutes of injection. In some standard PCNL cases, totally tubeless management was simulated by placement of a capped nephrostomy tube. Post-operative complications within 7 days were evaluated as the primary outcome. Results: The intraoperative MB test was performed in 91 PCNL cases: 60 mini-PCNLs (16 Fr access) and 31 standard PCNLs (24+ Fr access). Mini-PCNL cases were more likely to pass the MB test compared to standard PCNL cases (75% vs 38.7%, p = 0.001). Of the 45 mini-PCNL subjects who passed, 40 were left totally tubeless, resulting in two minor complications (urinary retention, obstructing ureteral stone fragment). In the standard PCNL cohort, 12 passed the MB test. Five were left totally tubeless and 3 simulated totally tubeless management with capped nephrostomy tubes; one subject had a transient postoperative creatinine elevation, and one required uncapping for steinstrasse. There were no other obstructive or infectious complications, and no surgical reintervention was required. Conclusions: An intraoperative methylene blue test is a simple test with high positive-predictive value to determine candidacy for totally tubeless PCNL in real time for both mini and standard PCNLs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.